Anti-TGR5 (C-Term)

TGR5, also known as GPBAR1, is a G protein-coupled receptor (GPCR) belonging to the bile acid receptor subclass. It is a plasma membrane-bound transmembrane protein and is primarily expressed in spleen and placenta. TGR5 is activated by the endogenous bile acids cholic acid (Cay-20250), lithocholic acid (Cay-20253), taurolithocholic acid (Cay-17275), deoxycholic acid (Cay-20756, Cay-18231), and chenodeoxycholic acid (Cay-10011286), among others. Activation of TGR5 by the synthetic agonist INT-777 (Cay-17678) decreases plasma triglyceride levels and urinary levels of albumin, thiobarbituric acid reactive substances (TBARS), and hydrogen peroxide, as well as prevents diabetic nephropathy, in a db/db mouse model of diabetes. Activation of TGR5 by INT-777 also prevents hepatic steatosis and increases in fat, liver, and brown adipose tissue mass in a mouse model of diet-induced obesity. Transgenic overexpression of TGR5 increases glucose tolerance, as well as plasma levels of insulin and glucagon-like peptide 1 (GLP-1), during an oral glucose tolerance test in mice fed a high-fat diet. Increased expression of TGR5 has been found in tissue samples from patients with intestinal-type adenocarcinoma or intestinal metaplasia, but not healthy mucosa. TGR5 protein levels are also increased in patient-derived Barrett's esophagous and esophageal adenocarcinoma tissues. Cayman's TGR5 (C-Term) Polyclonal Antibody can be used for Western blot and immunohistochemistry (IHC) applications. The antibody recognizes the C-terminal region of TGR5 from human samples.Synonyms: hBG37, GPBAR1, hGPCR19, GPR131, G Protein-Coupled Bile Acid Receptor 1, M-BAR, Membrane-Type Receptor for Bile Acids. Immunogen: Synthetic peptide from the C-terminal region of human TGR5. Formulation: (Request formulation change), 500 µl of peptide affinity-purified antibody. Storage Buffer: PBS, pH 7.2, with 50% glycerol and 0.02% sodium azide. Host: Rabbit. Applications: IHC and WB. UniProt Accession #: Q8TDU6.